Sanofi India (SANOFI)

FairStock Score: 39/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Near-zero leverage: Debt/Equity of 0.02 provides a strong balance sheet cushion.
• Exceptional historical capital efficiency: ROE 37.96% and ROCE 57.53%.
• High promoter holding of 60.40% aligns majority interests with minority shareholders.
• Dividend yield of 2.95% offers some income support despite the weak earnings phase.
• Latest quarter still profitable with net margin around 14.8%, showing base profitability.

Concerns

• Sharp fundamental deterioration: Sales down 18.47% and profits down 27.68%.
• Expensive valuation for negative growth: P/E 26.36 and P/B 9.21 are not margin-of-safety prices.
• Piotroski F-Score of 3/9 and FairStock Score of 21/100 signal financial stress and risk.
• Reported free cash flow of ₹358.27 lakh Cr appears nonsensical, undermining data reliability.

AI Analysis

A wise investor said the best business is a wonderful company at a fair price, not a fair company at a wonderful price. Sanofi India's fundamentals are impressive: near-zero debt at 0.02 debt/equity, a 37.96% ROE and a 57.53% ROCE. The promoter holds 60.40%, and the company pays a 2.95% dividend. That tells me the franchise has historically been a cash generator and minority shareholders are reasonably aligned. But I buy tomorrow's earnings, not yesterday's glorified ratios. Sales have contracted 18.47%, profits 27.68%. The latest quarter—₹420 Cr sales, ₹62 Cr profit—yields a net margin around 14.8%, respectable, but the growth trajectory is down. At ₹3,445.30, the market cap is ₹9,132 Cr. Paying 26.36 times earnings and 9.21 times book value for a shrinking business makes no sense. The Piotroski F-Score is 3/9; FairStock calls it 21/100, 'risky.' This is a deterioration signal, not a value signal. The 52-week range of ₹3,054 to ₹5,291 shows the crowd has already fled. Dividends help, but a 2.95% yield does not compensate for a 27.68% profit decline. The FCF figure as reported—₹358.27 lakh Cr—is clearly not credible; I disregard it. This is a possible turnaround, not a stalwart. I want to see evidence: quarterly sales stabilizing, F-Score rising, and margins recovering. Until then, a famous name and high ROE are not enough. Patience is part of investing, and waiting for a better price and better fundamentals is exactly what the situation demands.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer